Search Results

Filter
  • 1-10 of  1,247 results for ""INTERFERON alpha""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Tumour regression predicts better response to interferon therapy in melanoma patients: a retrospective single centre study.

  • Authors : Mezőlaki NE; Department of Dermatology and Allergology, Albert Szent-Györgyi Health Center, University of Szeged, Hungary.; Baltás E

Subjects: Melanoma*/Melanoma*/Melanoma*/pathology ; Skin Neoplasms*/Skin Neoplasms*/Skin Neoplasms*/pathology ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use

  • Source: Melanoma research [Melanoma Res] 2024 Feb 01; Vol. 34 (1), pp. 54-62. Date of Electronic Publication: 2023 Nov 13.Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9109623 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Academic Journal

Impaired activation of plasmacytoid dendritic cells via toll-like receptor 7/9 and STING is mediated by melanoma-derived immunosuppressive cytokines and metabolic drift.

  • Authors : Monti M; Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.; Ferrari G

Subjects: Melanoma*/Melanoma*/Melanoma*/metabolism ; Skin Neoplasms*/Skin Neoplasms*/Skin Neoplasms*/metabolism; Humans

  • Source: Frontiers in immunology [Front Immunol] 2024 Jan 03; Vol. 14, pp. 1227648. Date of Electronic Publication: 2024 Jan 03 (Print Publication: 2023).Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet

Record details

×
Academic Journal

[Efficacy of adjuvant programmed cell death 1 (PD-1) monoclonal antibody immunotherapy in Chinese patients with resected stage Ⅱ-Ⅲ melanoma].

  • Authors : Ren ZG; Department of Orthopedics, Shanghai Electric Power Hospital, Shanghai 200050, China.; Xu Y

Subjects: Melanoma*/Melanoma*/Melanoma*/drug therapy ; Melanoma*/Melanoma*/Melanoma*/pathology ; Skin Neoplasms*/Skin Neoplasms*/Skin Neoplasms*/drug therapy

  • Source: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2023 Nov 23; Vol. 45 (11), pp. 973-980.Publisher: Chinese Medical Association Country of Publication: China NLM ID: 7910681 Publication Model: Print Cited Medium: Print ISSN: 0253-3766

Record details

×
Academic Journal

Antitumor activity of pegylated human interferon β as monotherapy or in combination with immune checkpoint inhibitors via tumor growth inhibition and dendritic cell activation.

  • Authors : Wang R; Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China.; Zhang T

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/metabolism ; Adenocarcinoma*/Adenocarcinoma*/Adenocarcinoma*/drug therapy ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/pathology

  • Source: Cellular immunology [Cell Immunol] 2023 Nov-Dec; Vol. 393-394, pp. 104782. Date of Electronic Publication: 2023 Nov 03.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 1246405 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Efficacy and safety of interferon-alpha 1b combined with PD-1 monoclonal antibody in patients with unresectable stage IV melanoma: a retrospective study.

  • Authors : Zhu G; Department of Dermatology, Xijing Hospital, Fourth Military Medical University, 127 Changlexi Road, Xi'an, Shaanxi, 710032, People's Republic of China.; Shi Q

Subjects: Antibodies, Monoclonal*/Antibodies, Monoclonal*/Antibodies, Monoclonal*/therapeutic use ; Melanoma*/Melanoma*/Melanoma*/immunology ; Melanoma*/Melanoma*/Melanoma*/therapy

  • Source: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2023 Aug; Vol. 149 (9), pp. 6263-6269. Date of Electronic Publication: 2023 Jan 30.Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902060 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy.

  • Authors : Razaghi A; Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.; Durand-Dubief M

Subjects: Interferon Type I*/Interferon Type I*/Interferon Type I*/therapeutic use ; Melanoma*; Humans

  • Source: Frontiers in immunology [Front Immunol] 2023 Aug 24; Vol. 14, pp. 1249330. Date of Electronic Publication: 2023 Aug 24 (Print Publication: 2023).Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet

Record details

×
Academic Journal

Chemotherapy in combination with anti-PD-1 agents as adjuvant therapy for high-risk oral mucosal melanoma.

  • Authors : Wu Y; Department of Oral and Maxillofacial -Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhi Zao Ju Road, 200011, Shanghai, People's Republic of China.; College of Stomatology, Shanghai Jiao Tong University, 200011, Shanghai, People's Republic of China.

Subjects: Melanoma*/Melanoma*/Melanoma*/therapy ; Skin Neoplasms*/Skin Neoplasms*/Skin Neoplasms*/drug therapy; Humans

  • Source: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2023 Jun; Vol. 149 (6), pp. 2293-2300. Date of Electronic Publication: 2022 Sep 11.Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902060 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Editorial & Opinion

Flashback Foreword: Adjuvant Interferon α-2b for High-Risk Melanoma.

  • Authors : Schwartz GK; Columbia University, New York, NY.; Associate Editor, Journal of Clinical Oncology, Alexandria, VA.

Subjects: Melanoma*/Melanoma*/Melanoma*/drug therapy ; Skin Neoplasms*/Skin Neoplasms*/Skin Neoplasms*/drug therapy ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use

  • Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Jan 20; Vol. 41 (3), pp. 423-424.Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print Cited Medium: Internet

Record details

×
Academic Journal

IFNα and 5-Aza-2'-deoxycytidine combined with a dendritic-cell targeting DNA vaccine alter tumor immune cell infiltration in the B16F10 melanoma model.

  • Authors : Gordy JT; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.; Sandhu AK

Subjects: Melanoma* ; Vaccines, DNA* ; Cancer Vaccines*

  • Source: Frontiers in immunology [Front Immunol] 2023 Jan 19; Vol. 13, pp. 1074644. Date of Electronic Publication: 2023 Jan 19 (Print Publication: 2022).Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet

Record details

×
Academic Journal

Interferon-α1b for the treatment of metastatic melanoma: results of a retrospective study.

  • Authors : Shi Q; Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.; Liu L

Subjects: Interferon-alpha/Interferon-alpha/Interferon-alpha/*therapeutic use ; Melanoma/Melanoma/Melanoma/*drug therapy ; Skin Neoplasms/Skin Neoplasms/Skin Neoplasms/*drug therapy

  • Source: Anti-cancer drugs [Anticancer Drugs] 2021 Nov 01; Vol. 32 (10), pp. 1105-1110.Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9100823 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
  • 1-10 of  1,247 results for ""INTERFERON alpha""